Computational prediction and experimental validation associating FABP-1 and pancreatic adenocarcinoma with diabetes
2011

FABP-1 and Its Link to Pancreatic Cancer and Diabetes

Sample size: 134 publication 10 minutes Evidence: moderate

Author Information

Author(s): Sharaf Ravi N, Butte Atul J, Montgomery Kelli D, Pai Reetesh, Dudley Joel T, Pasricha Pankaj J

Primary Institution: Stanford University School of Medicine

Hypothesis

The study aimed to validate the association between FABP-1 and pancreatic adenocarcinoma, particularly in patients with diabetes.

Conclusion

There is a significant positive association between FABP-1 staining and pancreatic adenocarcinoma, especially in the presence of diabetes.

Supporting Evidence

  • FABP-1 staining was significantly associated with the diagnosis of pancreatic adenocarcinoma.
  • Diabetic pancreatic adenocarcinoma samples showed increased FABP-1 staining compared to normal samples.
  • The study identified FABP-1 as a potential biomarker for pancreatic cancer and diabetes.

Takeaway

Researchers found that a protein called FABP-1 is more common in pancreatic cancer, especially in people who also have diabetes.

Methodology

The study used tissue microarrays and immunohistochemistry to analyze FABP-1 staining in pancreatic tissue samples.

Potential Biases

Selection bias may have influenced the results due to the nonrandom sample collection.

Limitations

The study had a small sample size and was retrospective, which may affect the generalizability of the findings.

Participant Demographics

The sample included 134 patients, with a mix of ages and a history of diabetes, tobacco, and alcohol use.

Statistical Information

P-Value

0.004

Confidence Interval

95% CI 1.1-68

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1471-230X-11-5

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication